Journalartikel

Jahr der Veröffentlichung: 2021

Zeitschrift: Journal of Clinical Medicine

Bandnummer: 10

Heftnummer: 3

eISSN: 2077-0383

Open Access Status: Gold

DOI Link: https://doi.org/10.3390/jcm10030509

Verlag: MDPI

Abstract: 
Comorbidities in patients with rheumatoid arthritis (RA) are often associated with poor health outcomes and increased mortality. Treatment decisions should take into account these comorbidities due to known or suspected associations with certain drug classes. In clinical practice, it is critical to balance potential treatment benefit against the possible risks for comorbidities as well as the articular manifestations of RA. This review summarises the current literature relating to prevalence and risk factors for the important comorbidities of cardiovascular disease, infections, lymphomas and nonmelanoma skin cancers in patients with RA. The impact on patient outcomes and the interplay between these comorbidities and the therapeutic options currently available, including tumour necrosis factor inhibitors and newer biological therapies, are also explored. As newer RA therapies are developed, and patients gain wider and earlier access to advanced therapies, in part due to the emergence of biosimilars, it is important to consider the prevention or treatment of comorbidities as part of the overall management of RA.

Harvard-Zitierstil: Taylor, P., Atzeni, F., Balsa, A., Gossec, L., Mueller-Ladner, U. and Pope, J. (2021) The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review, Journal of Clinical Medicine, 10(3), Article 509. https://doi.org/10.3390/jcm10030509

APA-Zitierstil: Taylor, P., Atzeni, F., Balsa, A., Gossec, L., Mueller-Ladner, U., & Pope, J. (2021). The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. Journal of Clinical Medicine. 10(3), Article 509. https://doi.org/10.3390/jcm10030509